Linked Life Data

20499060

Source:http://linkedlifedata.com/resource/pubmed/id/20499060

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
9
pubmed:dateCreated
2010-6-28
pubmed:abstractText
A critical factor in clinical development of cancer immunotherapies is the identification of tumor-associated antigens that may be related to immunotherapy potency. In this study, protein microarrays containing >8,000 human proteins were screened with serum from prostate cancer patients (N = 13) before and after treatment with a granulocyte-macrophage colony-stimulating factor (GM-CSF)-secreting whole cell immunotherapy. Thirty-three proteins were identified that displayed significantly elevated (P <or= 0.05) signals in post-treatment samples, including three proteins that have previously been associated with prostate carcinogenesis, galectin-8, T-cell alternative reading frame protein (TARP) and TNF-receptor-associated protein 1 (TRAP1). Expanded analysis of antibody induction in metastatic, castration-resistant prostate cancer (mCRPC) patients (N = 92) from two phase 1/2 trials of prostate cancer immunotherapy, G-9803 and G-0010, indicated a significant (P = 0.03) association of TARP antibody induction and median survival time (MST). Antibody induction to TARP was also significantly correlated (P = 0.036) with an increase in prostate-specific antigen doubling time (PSADT) in patients with a biochemical (PSA) recurrence following prostatectomy or radiation therapy (N = 19) from in a previous phase 1/2 trial of prostate cancer immunotherapy, G-9802. RNA and protein encoding TARP and TRAP1 was up-regulated in prostate cancer tissue compared to matched normal controls. These preliminary findings suggest that antibody induction to TARP may represent a possible biomarker for treatment response to GM-CSF secreting cellular immunotherapy in prostate cancer patients and demonstrates the utility of using protein microarrays for the high-throughput screening of patient-derived antibody responses.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Sep
pubmed:issn
1432-0851
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
59
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1313-23
pubmed:meshHeading
pubmed-meshheading:20499060-Antibodies, pubmed-meshheading:20499060-Biomarkers, Pharmacological, pubmed-meshheading:20499060-Clinical Trials as Topic, pubmed-meshheading:20499060-Disease Progression, pubmed-meshheading:20499060-Galectins, pubmed-meshheading:20499060-Granulocyte-Macrophage Colony-Stimulating Factor, pubmed-meshheading:20499060-HSP90 Heat-Shock Proteins, pubmed-meshheading:20499060-High-Throughput Screening Assays, pubmed-meshheading:20499060-Humans, pubmed-meshheading:20499060-Immunotherapy, Adoptive, pubmed-meshheading:20499060-Male, pubmed-meshheading:20499060-Neoplasm Metastasis, pubmed-meshheading:20499060-Nuclear Proteins, pubmed-meshheading:20499060-Prognosis, pubmed-meshheading:20499060-Prostatic Neoplasms, pubmed-meshheading:20499060-Protein Array Analysis, pubmed-meshheading:20499060-Retrospective Studies, pubmed-meshheading:20499060-Survival Analysis, pubmed-meshheading:20499060-Treatment Outcome, pubmed-meshheading:20499060-Tumor Markers, Biological
pubmed:year
2010
pubmed:articleTitle
Antibody responses to galectin-8, TARP and TRAP1 in prostate cancer patients treated with a GM-CSF-secreting cellular immunotherapy.
pubmed:affiliation
Cell Genesys Inc., South San Francisco, CA 94080, USA.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't